GF CSI Innovative Drugs Industry ETF (515120) Rises 2.47%, with Scale Growing by RMB 393 Million Over the Past Week

NewTimeSpace (newtimespace.com) News, – As of 10:25 on August 11, 2026, GF Innovative Drug ETF (515120) rose 2.47%, poised for 3 consecutive gains, with its latest price at RMB 0.70. Over a longer horizon, as of August 10, 2026, the ETF had accumulated a gain of 10.63% over the past week.

In terms of liquidity, GF Innovative Drug ETF recorded a turnover rate of 4.01% during the session, with trading volume reaching RMB 505 million. Over a longer period, as of August 10, the ETF’s average daily turnover over the past week was RMB 1.037 billion, ranking among the top 2 comparable funds.

In terms of scale, the ETF’s scale grew by RMB 393 million over the past week, achieving significant growth and ranking 3rd among 7 comparable funds in new scale additions. (Data source: Wind)

In terms of units, the ETF’s share count grew by 2.699 billion units over the past 3 months, achieving significant growth and ranking 2nd among 7 comparable funds in new share additions. (Data source: Wind)

Data shows that leveraged funds are continuing to position themselves. The latest margin buying amount for GF Innovative Drug ETF reached RMB 99.3757 million, with its latest margin balance standing at RMB 371 million. (Data source: Wind)

As of August 10, the net value of GF Innovative Drug ETF had risen 45.90% over the past 2 years. In terms of return capability, as of August 10, 2026, since its inception, the ETF achieved a highest single‑month return of 23.00%, a longest consecutive winning streak of 5 months with a cumulative gain of 32.68%, and an average monthly return of 5.46% during up months. As of August 10, 2026, the ETF’s 3‑month excess annualized return over its benchmark was 5.58%.

In terms of drawdown, as of August 10, 2026, the ETF’s half‑year drawdown relative to its benchmark was 0.14%, indicating relatively low drawdown risk among comparable funds. The recovery period after drawdown was 36 days.

On fees, GF Innovative Drug ETF charges a management fee of 0.50% and a custody fee of 0.10%.

On tracking accuracy, as of August 10, 2026, the ETF’s 5‑year tracking error was 0.026%, the highest tracking precision among comparable funds.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The index selects no more than 50 representative listed company securities whose primary business involves innovative drug research and development as index samples, reflecting the overall performance of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.